SoWell Launches The First and Only Supplement System for GLP-1 Users to Thrive on the Medication

SoWell announced the launch of the only three-part supplement system designed specifically for GLP-1 users and their side effects: the SoWell GLP-1 Support System ($104.99). Dr. Alexandra Sowa, MD, board-certified obesity medicine specialist, and forthcoming author of ‘The Ozempic Revolution’ (HarperCollins, Winter 2025), developed this product from a decade of GLP-1 research and patient care to specifically meet the unique needs of individuals on a GLP-1 weight loss journey. Despite 50% of GLP-1 users experiencing side effects, individuals are left to navigate an overwhelming assortment of supplements that are not specifically formulated to their body’s new sensitivities or needs.

Currently, 1 in 8 Americans are using Ozempic or similar GLP-1 drugs, yet over 70% of users stop taking these life-changing medications within one year largely because of side effects they find too hard to navigate. This three-part supplement system is based on the latest clinical research and the founder’s decade-long experience working with GLP-1 patients. The SoWell GLP-1 Support System is formulated to target the unique side effects and requirements of GLP-1 users, providing comprehensive support to ensure a sustained and simplified journey on GLP-1 drugs. The product can be sold as a bundle of all three stick pack supplements, retailing for ($104.99) or available individually for flexibility: SoWell Electrolytes ($34.99), SoWell Protein ($44.99), and SoWell Fiber ($34.99).

The SoWell GLP-1 Support System extends far beyond an electrolyte, protein, and fiber supplement, combining 17 evidence-based ingredients that alleviate side effects like nausea, constipation, diarrhea, fatigue, headaches, muscle loss, weakened skin elasticity, and hair loss, all in easy-to-use stick packs. Each formulation in the protocol is enhanced with targeted ingredients to make the line more gut-friendly than alternatives and developed for the unique taste buds of GLP-1 users, who are more sensitive to overly sweet and artificial flavors. The entire system is low sugar, low carbohydrate, and free of artificial flavors, colorings, or sweeteners.

“As a physician specializing in internal and obesity medicine, I have spent over a decade working with GLP-1 patients and understanding their unique needs and challenges,” explains Dr. Alexandra Sowa, Founder of SoWell. “But other products on the market didn’t meet my standards and weren’t developed for GLP-1 users. There is a critical gap in the market when it comes to addressing the side effects and specific requirements of GLP-1 users on their weight loss journey. The SoWell GLP-1 Support System is designed to support and enhance the effectiveness of GLP-1 therapies while helping users achieve their health goals more comfortably and effectively.”

Dr. Sowa’s deep understanding of GLP-1 medications has enabled her patients to avoid the typical side effects of GLP-1 treatments. This insight drove the creation of the GLP-1 Support System, aiming to assist even more GLP-1 users throughout every step of their journey.

SoWell GLP-1 Support System Product Details:

Full GLP-1 Support System ($104.99): Includes the SoWell Electrolytes, SoWell Protein, and SoWell Fiber.

  • SoWell Electrolytes ($34.99): This daily electrolyte formula helps GLP-1 users maintain healthy hydration levels while simultaneously addressing nausea and fatigue with targeted ingredients like vitamin B6 and trace minerals. Since GLP-1 users can be sensitive to artificial and overly sweet flavors, this blend features a light, natural flavor with 0g sugar and 1g carb.
  • SoWell Protein ($44.99): By combining 25g whey isolate and collagen protein with digestive enzymes, this low-carb protein powder helps GLP-1 users maintain muscle mass, skin elasticity, and hair density as they lose weight without the digestive upset that other protein powders can cause.
  • SoWell Fiber ($34.99): GLP-1 medications slow the digestive process, which can lead to constipation and diarrhea. This triple-action blend of psyllium husk, guar gum, and apple pectin fiber works quickly to balance digestion while promoting long-term gut health. Enhanced with magnesium glycinate and 7.5 billion CFU probiotics, this one-of-a-kind formula gives GLP-1 users the gut support they need with 0g sugar and 1g net carb per serving.

For more information about SoWell or to order your first GLP-1 Support System, please visit here.

SourceSoWell

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”